ABSTRACT

Introduction

Coronavirus Disease 2019 is a contagious infection that has infected millions worldwide. The objective of this systematic review is to identify studies pertaining to antivirals, both as sole and combined therapies, in COVID-19 patients and review the clinical outcomes of these treatment methods.

Areas covered

A systematic review was conducted using Preferred Reporting Items or Systematic Reviews and Meta-analysis (PRISMA) guidelines. A literature search was done on Medline, Global Health, and EMBASE using keywords and MeSH terms relevant to COVID- 19 and antivirals. Limits were put on date to obtain articles between December 2019 to May 2020 (the time at which the search was performed). 776 articles were identified and screened. After screening, 16 studies were included. The narrative synthesis revealed three key themes (1) Use of antivirals only (such as lopinavir, umifenovir, and remdesivir), (2) Use of lopinavir-ritonavir alongside other treatments, and (3) Use of other antivirals in combination with other treatments.

Expert opinion

Using antivirals in combination with other treatments has potential; however, further randomized controlled trials with larger sample sizes are required to identify the best candidate components that should comprise combined treatments for COVID-19. This should optimize treatment efficacy and improve patient outcomes.

中文翻译：

---

抗病毒药对COVID-19的影响：系统评价

摘要

介绍

2019年冠状病毒病是一种传染性感染，已经感染了全球数百万人。这项系统评价的目的是确定在COVID-19患者中与抗病毒药有关的研究，作为单独疗法和联合疗法，并复习这些治疗方法的临床结果。

覆盖区域

使用首选报告项目或系统评价和荟萃分析（PRISMA）指南进行了系统评价。使用与COVID-19和抗病毒药物相关的关键字和MeSH术语，在Medline，Global Health和EMBASE上进行了文献检索。在2019年12月至2020年5月（进行搜索的时间）之间对获取文章的日期进行了限制。确定和筛选了776条文章。筛选后，包括16个研究。叙述的综合揭示了三个关键主题：（1）仅使用抗病毒药（例如洛匹那韦，umifenovir和remdesivir）；（2）与其他疗法一起使用lopinavir-ritonavir；以及（3）与其他疗法结合使用其他抗病毒药。

专家意见

与其他疗法联合使用抗病毒药有潜力；但是，还需要进行更大样本量的随机对照试验，以找出应包括COVID-19联合治疗的最佳候选成分。这应该优化治疗效果并改善患者预后。